SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)
$12 -2.4756 (-17.1019%)
Analysed SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) News Sources
Geopolitics, Beijing Regulatory Changes Lift Asian Stock Markets
20-04-2026
yahoo.com
Middle East Outlook Rattles Asian Stock Markets
02-04-2026
yahoo.com
Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
23-03-2026
yahoo.com
Middle East War, Oil Outlook Damps Asian Stock Markets
03-03-2026
yahoo.com
A Look At Sumitomo Pharma’s Valuation As AMCHEPRY Faces Key Japanese Regulatory Milestone
24-02-2026
yahoo.com
Geopolitics, Tech Gyrations Roil Asian Stock Markets
20-02-2026
yahoo.com
Tech, Trade Outlooks Lift Asian Exchanges in Holiday-Thinned Trading
18-02-2026
yahoo.com
China-Japan Pressures, Wall Street Cues Undercut Asian Stock Markets
08-01-2026
yahoo.com
Bank of Japan Outlook, Beijing Economic Report Roil Asian Stock Markets
29-12-2025
yahoo.com
Is Sumitomo Pharma’s 344% 2025 Surge Still Supported by Its Fundamentals?
10-12-2025
yahoo.com
What is the current price of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The current price of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is $12.
SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) since the previous trading day is $-2.4756.
SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) since the previous trading day is -17.1019%.
What is the most recent average sentiment score for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The most recent average sentiment score for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is 48 out of 100.
What is the most recent average sentiment for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The most recent sentiment for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is .
SEC-8K** Filing Available For SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.